Evidence map›Paper›PMID 36562592›Full record

ArticleThe oncologist2023

Using Tumor-Informed Circulating Tumor DNA (ctDNA)-Based Testing for Patients with Anal Squamous Cell Carcinoma.

Georges Azzi, Mehrad Tavallai, Vasily N Aushev, Allyson Koyen Malashevich, Gregory P Botta, Mohamedtaki A Tejani, Diana Hanna, Shifra Krinshpun, Meenakshi Malhotra, Adham Jurdi and 2 more

Abstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in The oncologist, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 13 papers, 1 of them a synthesis that pooled it.

0numbers the graph read from it
0cells of the map it votes in
13citing papers in PubMed, 1 pooled it
–field-weighted citation impact
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

13 citing papers in PubMed, 1 synthesis or guideline pooled it.

  1. Pooled it
  2. Review
  3. Article
  4. Review
  5. Article
  6. Article
  7. Review
  8. Article
  9. Article
  10. Factors Influencing Outcomes and Survival in Anal Cancer.Current oncology (Toronto, Ont.) · 2024
    Article
  11. Review
  12. Review
  13. Recent Advances in the Management of Anal Cancer.Healthcare (Basel, Switzerland) · 2023
    Review
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

12 authors.

Georges AzziHolyCross Medical Group, Ft. Lauderdale, FL, USA.
Mehrad TavallaiNatera, Inc., Austin, TX, USA.
Vasily N AushevNatera, Inc., Austin, TX, USA.
Allyson Koyen MalashevichNatera, Inc., Austin, TX, USA.
Gregory P BottaUC San Diego Health, San Diego, CA, USA.
Mohamedtaki A TejaniAdventHealth Cancer Institute, Orlando, FL, USA.
Diana HannaUSC Norris Comprehensive Cancer Center, Los Angeles, CA, USA.
Shifra KrinshpunNatera, Inc., Austin, TX, USA.
Meenakshi MalhotraNatera, Inc., Austin, TX, USA.
Adham JurdiNatera, Inc., Austin, TX, USA.
Alexey AleshinNatera, Inc., Austin, TX, USA.
Pashtoon M KasiWeill Cornell Medicine, New York, NY, USA.ORCID 0000-0002-5169-7085

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

backgroundAnal squamous cell carcinoma (SCCA) is an uncommon malignancy with a rising incidence that has a high cure rate in its early stages. There is an unmet need for a reliable method to monitor response to treatment and assist in surveillance. Circulating tumor DNA (ctDNA) testing has shown great promise in other solid tumors for monitoring disease progression and detecting relapse in real time. This study aimed to determine the feasibility and use of personalized and tumor-informed ctDNA testing in SCCA. PATIENTS AND

methodsWe analyzed real-world data from 251 patients (817 plasma samples) with stages I-IV SCCA, collected between 11/5/19 and 5/31/22. The tumor genomic landscape and feasibility of ctDNA testing was examined for all patients. The prognostic value of longitudinal ctDNA testing was assessed in patients with clinical follow-up (N = 37).

resultsWhole-exome sequencing analysis revealed PIK3CA as the most commonly mutated gene, and no associations between mutations and stage. Anytime ctDNA positivity and higher ctDNA levels (MTM/mL) were associated with metastatic disease (P = .004). For 37 patients with clinical follow-up, median follow-up time was 21.0 months (range: 4.1-67.3) post-diagnosis. For patients with stages I-III disease, anytime ctDNA-positivity after definitive treatment was associated with reduced DFS (HR: 28.0; P = .005).

conclusionsOur study demonstrates the feasibility of personalized and tumor-informed ctDNA testing as an adjunctive tool in patients with SCCA as well as potential use for detection of molecular/minuteimal residual disease, and relapse during surveillance. Prospective studies are needed to better evaluate the use of ctDNA testing in this indication.

Indexed as

Anus NeoplasmsCarcinoma, Squamous CellCell-Free Nucleic AcidsCirculating Tumor DNABiomarkers, TumorDNA, NeoplasmHumansMutationNeoplasm Recurrence, LocalBiomarkers, TumorCell-Free Nucleic AcidsCirculating Tumor DNADNA, Neoplasmanal squamous cell carcinomacirculating tumor DNAminimal/molecular residual diseaseprognostic biomarker

Identifiers

PMID36562592
PMCPMC10020810

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.